GeneDx Holdings Corp. Operating Income Loss

• GeneDx Holdings Corp. showed an increase of +43.7% in Operating Income Loss from 2024 to 2025.
• This data is from GeneDx Holdings Corp.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), GeneDx Holdings Corp.'s Operating Income Loss has grown by 57.0%.
• Historical annual values: Fiscal year 2025: -$13.08 million | Fiscal year 2024: -$23.21 million | Fiscal year 2023: -$180.60 million | Fiscal year 2022: -$667.65 million | Fiscal year 2021: -$446.15 million | Fiscal year 2020: -$241.99 million | Fiscal year 2019: -$30.41 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026